about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

With fresh com­pa­ny build­ing lessons from Abl­ynx, Ed­win Moses is ready to try it again as chair of neoanti­gen biotech ...

7 years ago
People

Bris­tol-My­ers vet Car­o­line Loew heads up Glympse Bio; Kalei­do nabs GSK's CMO Katharine Kno­bil

7 years ago
Peer Review

Ac­cused of milk­ing the CMS with co-pay kick­backs, J&J's Acte­lion set­tles case for $310M

7 years ago
Pharma

Join­ing hunt for hep B cure, Brii Bio inks maid­en deals fea­tur­ing VBI, Vir, WuXi with a big ap­petite for more

7 years ago
China
Pharma

Dis­graced VC Steven Bur­rill heads to prison with 30-month sen­tence for fraud, tax eva­sion

7 years ago
People

Trou­bled MiMedx ax­es a quar­ter of its work­force in the wake of a C-suite purge

7 years ago
R&D

For­get Hong Kong, Grail is now go­ing for a 2019 IPO in the US — Bloomberg

7 years ago
Financing

Roswell Park spin­out rais­es $35M from Chi­nese in­vestors to pur­sue one-two punch for adop­tive T cell ther­a­py

7 years ago
Financing

No­var­tis gains pri­or­i­ty re­view for SMA gene ther­a­py as in­vestors grap­ple with stick­er shock

7 years ago
Pharma
Cell/Gene Tx

FSD Phar­ma scoops GW Phar­ma ex­ec to guide cannabi­noid de­vel­op­ment; Zealand Phar­ma is look­ing for a new CEO

7 years ago
Peer Review

Low sales, high cost: Melin­ta slash­es HQ re­search staff as it strug­gles to grow an­tibi­otics rev­enue

7 years ago
R&D

Can a $1B IPO at­tract leery in­vestors on HKEX? WuXi AppTec is set to find out

7 years ago
Financing
China

At the cen­ter of a glob­al tem­pest, Jiankui He de­fends edit­ing the genes of 2 new­borns

7 years ago
China

Welling­ton, HBM lead €24M round as Adrenomed preps sep­tic shock treat­ment for hu­man test­ing

7 years ago
Financing

Rolling up its sleeves, Ax­o­vant scoops up five gene ther­a­py vets to pro­pel new pipeline

7 years ago
People

Roche ties up again with As­cle­tis — this time on a com­mer­cial part­ner­ship for hep B drug

7 years ago
Pharma

Gur­net Point-backed Au­re­gen taps Am­gen vet to lead; Ex-Roche RNA chief takes CEO post at Genevant

7 years ago
Peer Review

FDA opts to nail down REMS plan for Sage's land­mark post­par­tum de­pres­sion drug, de­lays fi­nal de­ci­sion

7 years ago
Pharma

Im­munother­a­py de­vel­op­er En­livex us­es Bioblast shell to re­verse merge its way on­to Nas­daq

7 years ago
Deals

Seek­ing an edge in the glob­al I/O race, Al­pham­ab On­col­o­gy loads up $100M-plus from mar­quee back­ers

7 years ago
Financing
China

Japan­ese bil­lion­aire Mik­i­tani takes full con­trol of Rakuten As­pyr­i­an; HOX Ther­a­peu­tics taps Karl Kee­gan as CEO

7 years ago
Peer Review

Bol­stered by promis­ing PhI­Ib snap­shot, uniQure plays catch-up with Spark in the race to a he­mo­phil­ia B gene ther­a­py

7 years ago
R&D
Cell/Gene Tx

Ab­b­Vie en­lists pro­tein degra­da­tion ex­perts at Mis­sion for a new bet on Alzheimer's, Parkin­son's

7 years ago
Pharma

Elud­ed by clear suc­cess in esophageal car­ci­no­ma, Mer­ck touts sub­group OS win for Keytru­da

7 years ago
R&D
First page Previous page 107108109110111112113 Next page Last page
A service from the Financial Times